Drug Trial Radar · NCT00005823
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Planned (sponsor's estimate)
Start
Dec 1998
Primary completion
Not stated
Study completion Dec 2007
Sponsor
- Lead sponsor
- Leukemia Research FundAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy. PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.
Conditions
- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytarabineDrug
daunorubicin hydrochlorideDrug
etoposideDrug
hydroxyureaDrug
idarubicinDrug
mitoxantrone hydrochlorideDrug
thioguanineDrug
tretinoinDrug
valspodarDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival
- Response achievement
- Response duration
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth Hospital at University of Birmingham
Birmingham, England, United Kingdom
University College Hospital
London, England, United Kingdom
University Hospital of Wales
Cardiff, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.